113 related articles for article (PubMed ID: 22469521)
41. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
42. [Clinical study of multiple myeloma: a report of 182 cases].
Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
[TBL] [Abstract][Full Text] [Related]
43. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
44. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
45. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution.
Bladé J; Esteve J; Rives S; Martínez C; Rovira M; Urbano-Ispizua A; Marín P; Carreras E; Montserrat E
Bone Marrow Transplant; 2000 Oct; 26(8):845-9. PubMed ID: 11081383
[TBL] [Abstract][Full Text] [Related]
46. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Riccardi A; Mora O; Tinelli C; Valentini D; Brugnatelli S; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Giordano M; Delfini C; Nicoletti G; Bergonzi C; Rinaldi E; Piccinini L; Ascari E
Br J Cancer; 2000 Apr; 82(7):1254-60. PubMed ID: 10755397
[TBL] [Abstract][Full Text] [Related]
47. [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Zhang GC; Peng AH; Zheng D; Su C; Xu DR; Tong XZ; Gu JL; Ding Y
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2140-3. PubMed ID: 19080477
[TBL] [Abstract][Full Text] [Related]
48. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
49. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
Ishak KJ; Caro JJ; Drayson MT; Dimopoulos M; Weber D; Augustson B; Child JA; Knight R; Iqbal G; Dunn J; Shearer A; Morgan G
Value Health; 2011; 14(5):672-8. PubMed ID: 21839405
[TBL] [Abstract][Full Text] [Related]
50. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.
Kim SJ; Kim K; Kim BS; Jo DY; Kang HJ; Kim JS; Mun YC; Kim CS; Sohn SK; Eom HS; Kwak JY; Shim H; Yoon HJ; Jin JY; Min CK; Shin H; Won JH; Lee JJ; Kwon JH; Joo YD; Do YR; Kim SH; Oh S; Suh C; Lee J; Yoon SS; Kim MK; Bang SM; Ryoo HM; Kim BS; Kim H; Kim HJ; Kim YS; Park CW; Lee GW; Shin HJ; Park SK; Park JS; Kim HY; Lee DS; Lee JH;
Acta Haematol; 2009; 122(4):200-10. PubMed ID: 19887776
[TBL] [Abstract][Full Text] [Related]
51. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
[TBL] [Abstract][Full Text] [Related]
52. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
[TBL] [Abstract][Full Text] [Related]
53. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
[TBL] [Abstract][Full Text] [Related]
54. Novel agents have a significant impact on survival of patients with multiple myeloma.
Lamm W; Eder S; Bojic M; Zielinski CC; Drach J
Wien Klin Wochenschr; 2015 Feb; 127(3-4):92-7. PubMed ID: 25609569
[TBL] [Abstract][Full Text] [Related]
55. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.
Pozzi S; Marcheselli L; Bari A; Liardo EV; Marcheselli R; Luminari S; Quaresima M; Cirilli C; Ferri P; Federico M; Sacchi S
Br J Haematol; 2013 Oct; 163(1):40-6. PubMed ID: 23889344
[TBL] [Abstract][Full Text] [Related]
56. [A multi-centers clinical study of different treatment outcomes of 332 patients with multiple myeloma].
Xue K; Qiu LG; Liu T; Hou J; Huang XJ; Ma J; Chen XQ; Yu L; Jin J; Wu DP; Wu YJ; Meng FY; Li JY; Chen WM; Wang C; Wang JM; Huang ZL; Zou P; Lou SF; Ouyang J; Zhou F; Du X; Shen ZX
Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):98-101. PubMed ID: 18683792
[TBL] [Abstract][Full Text] [Related]
57. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
Terpos E; Ntanasis-Stathopoulos I; Roussou M; Kanellias N; Fotiou D; Migkou M; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Kastritis E; Dimopoulos MA
Ann Hematol; 2020 Jun; 99(6):1257-1264. PubMed ID: 32382768
[TBL] [Abstract][Full Text] [Related]
58. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.
Jung SH; Cho MS; Kim HK; Kim SJ; Kim K; Cheong JW; Kim SJ; Kim JS; Ahn JS; Kim YK; Yang DH; Kim HJ; Lee JJ;
BMC Cancer; 2016 Aug; 16():613. PubMed ID: 27501959
[TBL] [Abstract][Full Text] [Related]
59. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.
Gavriatopoulou M; Fotiou D; Koloventzou U; Roussou M; Migkou M; Ntanasis-Stathopoulos I; Kanellias N; Ziogas DC; Panagiotidis I; Gika D; Eleutherakis-Papaiakovou E; Terpos E; Kastritis E; Dimopoulos MA
Leuk Lymphoma; 2019 Mar; 60(3):619-628. PubMed ID: 30628505
[TBL] [Abstract][Full Text] [Related]
60. Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate.
Niesvizkya R; Choy CG; Siegel D; Lyons L; Michaeli J
Leuk Lymphoma; 2002 Mar; 43(3):603-5. PubMed ID: 12002765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
